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Abstract
Today, scientists are often encouraged to custom-design vaccines based on a particular country or
clade. Here, we review the scientific literature and then suggest that the overwhelming endeavor
to produce a unique vaccine for every world region or virus subtype may not be necessary.
Clade, country or region-specific vaccines
It is generally agreed that HIV-1 arose decades ago by
transfer of virus from chimps to humans [1]. The subse-
quent travel of infected persons and the continued prac-
tice of high-risk behaviors fostered virus transmission to
virtually every world region. Once HIV-1 awareness was
heightened and HIV-1 sequencing projects were imple-
mented, regional similarities of viral sequences, presuma-
bly a consequence of the founder effect, became evident.
Clade designations (e.g. clade A, B, C) were then used as a
means to categorize viruses based on genetic sequence;
thus such clade designations also tended to cluster viruses
according to geographical location. Today, due to contin-
uous virus transmission, mutation and recombination,
the demarcation of HIV-1 subtypes has become increas-
ingly blurred, and the categorization of viruses by clade is
increasingly difficult [2-5]. Nonetheless scientists are cur-
rently encouraged to custom-design vaccines based on a
particular country or clade [6-11]. To this end, a single
viral sequence may be selected, possibly based on a for-
mula of ancestry or consensus, to represent all other
viruses in the targeted category.
Designing vaccines in this way prompts careful considera-
tion: must a unique vaccine be prepared to represent every
clade, country or region of the world? If so, how will this
be accomplished and for which country should first vac-
cines be produced? Who will decide? The complexity of
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it encourage a second look at the strategy. Review of the
scientific literature may provide reassurance that the
seemingly unachievable endeavor to custom-produce a
vaccine for every clade, country or region may not be nec-
essary.
Do immune responses discriminate between 
clades?
While differences in encoded protein sequence may per-
mit discrimination between certain HIV-1 subtypes, suc-
cessful vaccine development requires that viral proteins
elicit protective immune responses, regardless of
sequence. It has long been known that clades, as defined
by genetic sequence, do not correspond to immunotypes,
as defined by mutually exclusive immune responses [12-
14]. Both B- and T-cells elicited by a virus from one clade
may recognize viruses from other clades. This cross-clade
responsiveness is explained by the fact that the B- and T-
cells recognize precise epitopes rather than the overall
sequence similarity of viruses. Antibody binding depends
on three-dimensional structure, and the molecular struc-
tures bound by antibodies can occur on proteins that dif-
fer widely in primary sequence. T-cells recognize peptides
in association with Class I or Class II MHC molecules, but
like B-cells, T-cells can cross-react with non-identical tar-
gets. Conversely, two viruses may have 99% sequence
similarity, yet a particular neutralizing antibody or T-cell
receptor may discriminate between them. This discrimi-
nation may be due to a single amino acid change within
the receptor contact site or in a sequence that alters
epitope display [15,16]. Thus it is the detail of epitope and
epitope context, not overall sequence similarity that
defines lymphocyte specificity.
Cross-clade protection is achieved by priming 
the immune system with diverse viral sequences 
from a single clade
The issues described above suggest that although a single-
component vaccine may not be sufficient to target any
clade, a cocktail vaccine, designed to represent the natural
diversity of HIV-1, may be sufficient to target all clades.
The latter point is supported by studies of HIV-1-infected
humans and SIV-infected macaques. Although infected
subjects cannot clear endogenous virus (due to its seques-
tration in "privileged" sites, hidden from the immune sys-
tem), most individuals are resistant to super-infection
[17-22]. This protection likely arises as the result of many
successive rounds of endogenous viral mutation in the
infected host. Each time an immune response is elicited in
the periphery of an infected subject, new virus mutants
appear [23,24]. The new viruses, by definition, have
altered T- and B-cell determinants, allowing escape from
the established antibodies and T-cell receptors. Following
several rounds of immune response and virus escape, the
B- and T-cells are primed to recognize a broad spectrum of
determinants [25]. Thus, superinfections are rare, even in
subjects likely to have been serially exposed to viruses
from different clades. The rare double infections in
humans (explaining the origin of virus recombinants [4])
are perhaps a consequence of (i) drug regimens which
block the natural evolution of virus in the infected subject,
(ii) repeated HIV-1 exposures prior to maturation of the
adaptive immune response, and/or (iii) disease-related
immunodeficiency.
The fact that a mature immune response to HIV-1 cannot
clear sequestered virus, but can prevent super-infection
emphasizes the importance of priming the system
preemptively. Similar considerations pertain to the design
of vaccines against human herpesviruses (e.g. VZV and
EBV), as these viruses provoke both lifelong infections
and long-term protective immunity to superinfection. As
with the successful VZV vaccine [26], an effective HIV-1
vaccine should be administered before virus exposure,
infection and sequestration.
Could a cocktail vaccine ever be large enough to 
prevent HIV-1 infections?
Perhaps careful vaccine formulation will preclude the
need for assembly of enormous cocktails. Consideration
that envelope structure is constrained by function suggests
that the formulation of an effective envelope-based vac-
cine is feasible. The virus envelope must bind target cells
to mediate infection, and only a few target cell receptor
molecules (e.g. CD4, CCR5, CXCR4), have been
described. Therefore, the number of discrete envelope
shapes that maintain full cell-binding potential and func-
tion is likely to be limited [27]. Because the virus envelope
is the target of both neutralizing antibodies and T cells,
the strengths of both arms of the immune system may be
harnessed by an envelope-based vaccine cocktail [28-30].
Diverse proteins need not be cross-inhibitory. In fact,
type-specific immune responses have been recognized
toward a single envelope construct represented as only 1%
of a mixed vaccine [31]. Cocktail vaccines are effective in
controlling other diverse pathogens (e.g. pneumococcus,
poliovirus), despite early doubts about their prospect of
success [32].
Clade, Country or Region-specific HIV Vaccines 
may not be necessary
The assembly of envelope cocktail vaccines will probably
be necessary to represent the natural diversity of HIV-1,
even within a single clade. Careful vaccine design may
reveal a cocktail formulation able to prevent virus infec-
tions in every world region, and to overcome the political
and financial dilemmas associated with the production of
clade, country or region-specific vaccines.Page 2 of 3
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